Adicet Bio Inc To Discuss ADI-001 Clinical Update Call Transcript
Thanks, everyone, for joining us. On the call today from Adicet are Chen Schor, President and Executive Officer; Dr. Francesco Galimi, Chief Medical Officer; Nick Harvey, Chief Financial Officer; and Dr. Blake Aftab, Chief Scientific Officer.
Before we begin, I'd like to remind you that various remarks that we make on this call contain forward-looking statements that are made under the safe harbor provisions of the securities laws, including, but not limited to, express or implied statements regarding the potential safety, durability, tolerability and efficacy of ADI-001.
Due to progress of ADI-001 in patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma, or NHL, including selection of a recommended Phase II dose, expectations regarding future discussions with regulators and regulatory filings for product candidates in the company's pipeline and timing for the potentially pivotal Phase II study of ADI-001 in post CAR T LBCL patients.
In addition to our prepared remarks, we may make forward-looking statements in response to questions, including, for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
